Making Gains in HFpEF: An Appraisal of Where We Are Now

Published: 27 June 2022

  • Views:

    Views Icon 2664
  • Likes:

    Heart Icon 7


In this symposium, part of Heart Failure Online 2022, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with a left ventricular ejection fraction >40%.


In addition to hearing about the data which led to changes in the recent ACC guidelines, the faculty also explore the impact of clinical inertia and the remaining challenges in HFpEF management.

This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. It is not intended for US or UK based healthcare professionals.

Key Learning Objectives

Upon participation in this programme physicians should be able to:

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

More from this programme

Part 1

Patient Case – Typical Patient With HFpEF

Part 2

SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell

Part 3

Early Initiation of Foundational Therapy in HF: Why the Urgency?

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

Director of the Heart Failure and Heart Transplant Clinics

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.

She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of 

View full profile
Javed Butler

Javed Butler

Professor of Medicine

Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.

He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.


View full profile
Carolyn Lam

Carolyn Lam

Professor and Senior Consultant

Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.

View full profile